Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
Dexcom’s Stelo continuous glucose monitor (CGM) for those with Type 2 diabetes is starting to use generative AI to write weekly reports with “more personalized tips, recommendations, and education ...
DexCom Inc. DXCM recently announced the direct connectivity of the Dexcom G7 Continuous Glucose Monitoring (CGM) system with the Apple Watch. This added feature is now available to users in the United ...
Stelo is an over-the-counter CGM that pokes through the skin to measure real-time blood sugar levels. The sensor launched in August and can be used by any adult who doesn't take insulin. The report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results